Xeris Biopharma Holdings, Inc. XERS
10.35 USD +0.18 (+1.77%)
At closeNov 3, 2026, 4:24 PM EST
10.35 0.00 0.00%
After hours · Nov 3, 4:24 PM ET
10.17 Day range 10.56
5.25 52-week range 11.42
- YTD
- +31.85%
- 1 year
- +4.55%
News
defenseworld.net Xeris Biopharma (NASDAQ:XERS) vs. Cocrystal Pharma (NASDAQ:COCP) Head-To-Head Contrast Cocrystal Pharma (NASDAQ: COCP - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare…
businesswire.com Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the…
gurufocus.com Xeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Overvalued -- GF Score: 66/100 On October 23, 2026, Xeris Biopharma Holdings Inc (XERS) shares fell 6.1% to a current price of $10.20, within a 52-week range of $5.25 to $11.42. This price mo
gurufocus.com Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives
businesswire.com Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the…
defenseworld.net Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison Organon and Co. (NYSE: OGN - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses…
businesswire.com Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REINFORCES LEADERSHIP IN ENDOCRINOLOGY WITH DATA DISCLOSURES SPANNING COMMERCIAL PORTFOLIO & PIPELINE AT MULTIPLE SCIENTIFIC MEETINGS.
benzinga.com Xeris Biopharma Files Patent Infringement Lawsuits Related To Its KEYEVIS Product In U.S. District Court In New Jersey On October 13, 2026, Xeris Biopharma Holdings, Inc. (the "Company"), through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District…
fool.com Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
benzinga.com Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14 Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $12 to $14.
benzinga.com Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call Xeris Biopharma Holdings (NASDAQ:XERS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs.…
defenseworld.net Analyzing Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT) Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
businesswire.com Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative…
defenseworld.net Xeris Biopharma (NASDAQ:XERS) Shares Climb 5.2% – Here’s What Happened Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) traded up 5.2% during mid-day trading on Monday. The company traded as high as $9.38 and last traded at $9.5750. Approximately 460,484…
reuters.com Lundbeck expresses interest in buying Xeris, Bloomberg News reports Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma , Bloomberg News reported on Tuesday, citing people familiar with the matter.
benzinga.com Lundbeck Is Said To Express Interest In Buying Xeris Biopharma, Bloomberg Reports - Bloomberg
benzinga.com TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
defenseworld.net Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Hold” by Analysts Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat…
benzinga.com Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16 Leerink Partners analyst Roanna Ruiz maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $12 to $16.
seekingalpha.com Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript
gurufocus.com Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing i
benzinga.com Xeris Biopharma To Host XP‑8121 Program Overview Detailing Phase 3 Study And Commercial Opportunity; Topline Results Expected In Late 2028; FDA Approval And Launch Anticipated In 2030 Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030The Company expects XP-8121 peak net revenue…
businesswire.com Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative…
defenseworld.net Connor Clark & Lunn Investment Management Ltd. Takes $1.01 Million Position in Xeris Biopharma Holdings, Inc. $XERS Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) during the second quarter, according to its most recent Form 13F…
defenseworld.net Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Hold” by Brokerages Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) has received an average recommendation of "Hold" from the six brokerages that are covering the firm, MarketBeat Ratings reports. One…
businesswire.com Xeris Announces Details for XP-8121 Program Overview Webinar CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative…
seekingalpha.com Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth across all three commercial products. 2025 revenue guidance of $255M–$275M implies 30% growth for…- benzinga.com Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12 Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.
benzinga.com Xeris Biopharma Holdings Q2 EPS $(0.18) Misses $0.00 Estimate, Sales $92.100M Beat $90.225M Estimate Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.00 by Infinity percent. This is a 1700 percent decrease over…- benzinga.com Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $380.000M-$390.000M to $385.000M-$390.000M vs $385.229M Est Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $380.000 million-$390.000 million to $385.000 million-$390.000 million vs $385.229 million estimate.
benzinga.com Xeris Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Regarding Its Patent Application Entitled Compositions And Methods Of Use Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and…
benzinga.com Xeris Biopharma Enters Separate Exchange Agreements With Certain Holders Of Its 8.00% Convertible Senior Notes Due 2028 To Retire ~$23M Of The Notes For ~$23M In Cash And A Number Of Shares Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of…- benzinga.com Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $375.000M-$390.000M to $380.000M-$390.000M vs $383.864M Est Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $375.000 million-$390.000 million to $380.000 million-$390.000 million vs $383.864 million estimate.
- benzinga.com Xeris Biopharma Holdings Q1 EPS $0.01 Beats $(0.00) Estimate, Sales $83.127M Beat $79.992M Estimate Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.00) by Infinity percent. This is a 116.67 percent increase over…
benzinga.com HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $10 price target.
benzinga.com Xeris Biopharma Holdings Q4 Earnings Assessment - benzinga.com Xeris Biopharma Holdings Sees FY2026 Sales $375.000M-$390.000M vs $368.100M Est Xeris Biopharma Holdings (NASDAQ:XERS) sees FY2026 sales of $375.000 million-$390.000 million vs $368.100 million analyst estimate.
- benzinga.com Xeris Biopharma Holdings Q4 EPS $0.06 Beats $0.04 Estimate, Sales $85.807M Beat $82.340M Estimate Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.04 by 62.16 percent. This is a 300 percent increase over losses…
benzinga.com Earnings Scheduled For March 2, 2026 
benzinga.com Why Are Shares Of Xeris Biopharma Falling Friday? Xeris Biopharma Holdings shares are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.
benzinga.com A Peek at Xeris Biopharma Holdings's Future Earnings - benzinga.com Xeris Biopharma's Subsidiaries, Xeris Pharmaceuticals And Strongbridge Dublin Limited, File Recorlev Patent Infringement Lawsuit; Filed Patent Infringement Lawsuit Related To Recorlev Against Torrent Pharmaceuticals & Somerset Therapeutics Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $10 price target.
benzinga.com Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session - benzinga.com Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9 Barclays analyst Glen Santangelo initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight rating and announces Price Target of $9.
- benzinga.com Xeris Biopharma Holdings Raises FY2025 Sales Guidance from $280.000M-$290.000M to $285.000M-$290.000M vs $286.467M Est Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2025 sales outlook from $280.000 million-$290.000 million to $285.000 million-$290.000 million vs $286.467 million estimate.
benzinga.com Xeris Biopharma Holdings Q3 Sales $74.380M Beat $74.180M Estimate Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly sales of $74.380 million which beat the analyst consensus estimate of $74.180 million by 0.27 percent. This is a 37.06 percent increase over…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com American Regent And Xeris Pharmaceuticals Launch Gvoke VialDx, First Concentrated Liquid Glucagon For Diagnostic GI Procedures First concentrated, ready-to-dilute liquid glucagon available for diagnostic proceduresSHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire/ -- American Regent, Inc.® is pleased to announce the commercial launch…
- benzinga.com HC Wainwright & Co. Assumes Xeris Biopharma Holdings at Buy, Announces Price Target of $10 HC Wainwright & Co. analyst Brandon Folkes assumes Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy rating and announces Price Target of $10.